AI-Enabled POC Device Detects Cancers Without Biopsies
|
By LabMedica International staff writers Posted on 15 Sep 2022 |

Researchers have developed a unique type of nanoparticle called a “nanorattle” that greatly enhances light emitted from within its outer shell. Loaded with light scattering dyes called Raman reporters commonly used to detect biomarkers of disease in organic samples, the approach can amplify and detect signals from separate types of nanoprobes without needing an expensive machine or medical professional to read the results. In a small proof-of-concept study, the nanorattles accurately identified head and neck cancers through an AI-enabled point-of-care device that could revolutionize how these cancers and other diseases are detected in low-resource areas to improve global health.
To make nanorattles, researchers at Duke University (Durham, NC, USA) start with a solid gold sphere about 20 nanometers wide. After growing a layer of silver around the gold core to make a larger sphere (or cube), they use a corrosion process called galvanic replacement that hollows out the silver, creating a cage-like shell around the core. The structure is then soaked in a solution containing positively charged Raman reporters, which are drawn into the outer cage by the negatively charged gold core. The outer hulls are then covered by an extremely thin layer of gold to lock the Raman reporters inside. The result is a nanosphere (or nanocube) about 60 nanometers wide with an architecture that resembles a rattle - a gold core trapped within a larger outer silver-gold shell. The gap between the two is only about a few nanometers, which is just large enough to fit the Raman reporters. Those tight tolerances are essential to controlling the Raman signal enhancement the nanorattles produce.
When a laser shines on the nanorattles, it travels through the extremely thin outer shell and hits the Raman reporters within, causing them to emit light of their own. Because of how close the surfaces of the gold core and the outer gold/silver shell are together, the laser also excites groups of electrons on the metallic structures, called plasmons. These groups of electrons create an extremely powerful electromagnetic field due to the plasmons’ interaction of the metallic core-shell architecture, a process called plasmonic coupling, which amplifies the light emitted by the Raman reporters millions of times over. The researchers applied the nanorattle technology to a lab-on-a-stick device capable of detecting head and neck cancers, which appear anywhere between the shoulders and the brain, typically in the mouth, nose and throat. Survival rate for these cancers have hovered between 40 and 60% for decades. While those statistics have improved in recent years in the U.S., they have gotten worse in low-resource settings, where risk factors such as smoking, drinking and betel nut chewing are much more prevalent.
The prototype device uses specific genetic sequences that act like Velcro for the biomarkers the researchers are looking for - in this case, a specific mRNA that is overly abundant in people with head and neck cancers. When the mRNA in question is present, it acts like a tether that binds nanorattles to magnetic beads. These beads are then concentrated and held in place by another magnet while everything else gets rinsed away. Researchers can then use a simple, inexpensive handheld device to look for light emitted from the nanorattles to see if any biomarkers were caught. In the experiments, the test determined whether or not 20 samples came from patients that had head and neck cancer with 100% accuracy. The experiments also showed that the nanorattle platform is capable of handling multiple types of nanoprobes, thanks to a machine learning algorithm that can tease apart the separate signals, meaning they can target multiple biomarkers at once.
“In low-resource settings, these cancers often present in advanced stages and result in poor outcomes due in part to limited examination equipment, lack of trained healthcare workers and essentially non-existent screening programs,” said Walter Lee, professor of head and neck surgery & communication sciences and radiation oncology at Duke, and a collaborator on the research. “Having the ability to detect these cancers early should lead to earlier treatment and improvement in outcomes, both in survival and quality of life,” Lee said. “This approach is exciting since it does not depend on a pathologist review and potentially could be used at the point of care.”
“Many mRNA biomarkers are overly abundant in multiple types of cancers, while other biomarkers can be used to evaluate patient risk and future treatment outcome,” said Tuan Vo-Dinh, the R. Eugene and Susie E. Goodson Distinguished Professor of Biomedical Engineering and professor of chemistry at Duke. “Detecting multiple biomarkers at once would help us differentiate between cancers, and also look for other prognostic markers such as Human Papillomavirus (HPV), and both positive and negative controls. Combining mRNA detection with novel nanorattle biosensing will result in a paradigm shift in achieving a diagnostic tool that could revolutionize how these cancers and other diseases are detected in low-resource areas”.
Related Links:
Duke University
Latest Molecular Diagnostics News
- Four-Gene Blood Test Rules Out Bacterial Lung Infection
- New PCR Test Improves Diagnostic Accuracy of Bacterial Vaginosis and Candida Vaginitis
- New Serum Marker-Editing Strategy to Improve Diagnosis of Neurological Diseases
- World’s First Genetic Type 1 Diabetes Risk Test Enables Early Detection
- Blood Test to Help Low-Risk Gastric Cancer Patients Avoid Unnecessary Surgery
- First-Of-Its-Kind Automated System Speeds Myeloma Diagnosis
- Blood Protein Profiles Predict Mortality Risk for Earlier Medical Intervention
- First Of Its Kind Blood Test Detects Gastric Cancer in Asymptomatic Patients
- Portable Molecular Test Detects STIs at POC in 15 Minutes
- Benchtop Analyzer Runs Chemistries, Immunoassays and Hematology in Single Device
- POC Bordetella Test Delivers PCR-Accurate Results in 15 Minutes
- Pinprick Blood Test Could Detect Disease 10 Years Before Symptoms Appear
- Refined C-Reactive Protein Cutoffs Help Assess Sepsis Risk in Preterm Babies
- Blood Test Accurately Detects Brain Amyloid Pathology in Symptomatic Patients
- New Molecular Test Improves Diagnostic Accuracy of Lyme Disease
- New Genetic Test Enables Faster Diagnosis of Rare Diseases
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channelRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channelAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read more
AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment
Complex digital biopsy images that typically take an expert pathologist up to 20 minutes to assess can now be analyzed in about one minute using a new artificial intelligence (AI) tool. The technology... Read moreTechnology
view channel
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more




 assay.jpg)



